Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
motexafin gadolinium
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Motexafin Gadolinium Given Concurrently With Temozolomide and Fractionated Radiotherapy in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0513
, NCT00305864
2.
Phase II Study of Concurrent and Adjuvant Temozolomide With Radiotherapy in Young Patients With Diffuse Pontine Gliomas
Phase:
Phase II
Type:
Diagnostic, Supportive care, Treatment
Status:
Active
Age:
2 to 21
Sponsor:
Other
Protocol IDs:
CCLG-CNS-2007-04
, CNS 2007 04, EU-20746, EUDRACT-2007-001768-60, NCT00514397
3.
Ferumoxytol and Gadolinium Magnetic Resonance Imaging (MRI) at 3T and 7T in Patients With Malignant Brain Tumors
Phase:
Phase II
Type:
Diagnostic
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
OHSU-2864
, NIH, NINDS, 5 R01 NS053468 02, NCT00659126
4.
Phase II Pilot Study of Neoadjuvant Sunitinib Malate Followed by Cytoreductive Nephrectomy and Adjuvant Sunitinib Malate in Patients With Stage IV Renal Cell Carcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UPCC-10807
, UPCC 10807, PFIZER-807184, NCT00717587
5.
Phase II Pilot Study of Motexafin Gadolinium Combined With High-Dose Methotrexate-Based Chemotherapy, Rituximab, and Whole-Brain Radiotherapy in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
NU-05H7
, NU 05H7, PCI-P-NU-05H7, NCT00734773
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute